Eviagenics closes financing round for EUR 1.3 million to commercialize its technology platform

Eviagenics, a French biotech company, is pleased to announce the closing of a series A financing round to scale up its technical and commercial development. At this occasion the FCPR Emertec 4 managed by Emertec Management, CEA Investissement, and Genopole Premier Jour managed by CapDecisif Management provide a total contribution of EUR 1.3 million.

Located in the incubator Paris Sante Cochin Eviagenics has developed an innovative technology, the in vivo recombination, which allows to assemble and recombine complete metabolic pathways directly in living cells. This unique technology enables not only to improve the production of proteins and multi-enzyme complexes, but also to generate new molecules for numerous applications including green chemistry, nutrition and pharmaceuticals.

"The chemical and pharmaceutical industries are constantly seeking to replace conventional chemical production processes by environmentally friendly manufacturing processes based on biocatalysis. In addition, they have an urgent need to develop new products. Our technology offers the ideal solution for the optimization of bioprocesses and the development of new products since it is the only technology that enables to assemble and improve complete metabolic pathways in a highly efficient way", commented Rudy Pandjaitan, CEO of the company.

"The funds raised will be used to commercialize our technology platform through collaborations with leading chemical and pharmaceutical companies, but most importantly to develop our own in-house products such as biopolymers, alcohols, or polyphenols for applications in the chemical and health industry," added Rudy Pandjaitan.




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers call for ethical guidance on use of AI in healthcare